Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AQUAPHYLLIN vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular c AMP and c GMP, leading to bronchodilation and anti-inflammatory effects.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Maintenance treatment of asthma,Chronic obstructive pulmonary disease (COPD) exacerbations
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Terminal elimination half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in neonates and up to 30 hours in cirrhosis.
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Primarily hepatic via CYP1A2, with minor contributions from CYP3A4 and CYP2E1.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Renal: 90-95% unchanged; biliary/fecal: <5%.
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
Approximately 40% bound to albumin.
Approximately 70% bound to plasma proteins, primarily albumin.
0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid.
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Oral: 85-95%; intramuscular: 75-90%.
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
No adjustment required.
No adjustment required as drug is primarily hepatically metabolized.
In Child-Pugh Class B or C, reduce dose by 50% and monitor serum theophylline levels.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Loading dose: 5 mg/kg orally. Maintenance: 4 mg/kg orally every 6 hours for children 1-9 years; 3 mg/kg orally every 6 hours for children 10-16 years. Maximum daily dose: 24 mg/kg.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Use lower initial dose (e.g., 200 mg orally every 8 hours) and titrate slowly; monitor serum theophylline levels due to decreased clearance.
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
None
None.
Cardiovascular events: arrhythmias, tachycardia, hypotension,Seizures in patients with history of seizure disorder,Significant drug interactions with CYP1A2 inhibitors (e.g., cimetidine, fluoroquinolones) and inducers (e.g., smoking, rifampin),Overdose risk: narrow therapeutic index, monitor serum levels
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to theophylline or other xanthines,Active seizure disorders (relative),Uncontrolled cardiac arrhythmias
Hypersensitivity to theophylline or any component of the formulation.
Avoid large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase theophylline levels and risk of toxicity. High-protein, low-carbohydrate diets may decrease theophylline metabolism; low-protein, high-carbohydrate diets may increase metabolism. Consistent dietary habits are recommended. Charcoal-broiled meats may increase metabolism.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
Theophylline (Aquaphyllin) is pregnancy category C. First trimester: No well-controlled studies; risk cannot be ruled out. Second/third trimesters: Increased risk of neonatal apnea, tachycardia, and jitteriness due to transplacental passage. Maternal toxicity at high doses may cause fetal hypoxia.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Theophylline is excreted in breast milk with M/P ratio approximately 0.6-0.7. Infant plasma levels may reach 10-50% of maternal levels. Monitor infant for irritability, insomnia, and feeding difficulties. Use caution and consider alternative agents if infant is premature or has cardiovascular disease.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
Pregnancy increases theophylline clearance by 30-50% due to increased hepatic metabolism and renal perfusion. Dose may need to be increased by 30% to maintain therapeutic levels (5-15 mcg/m L). Monitor serum levels frequently and adjust accordingly.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
Aquaphyllin (theophylline) has a narrow therapeutic index; serum levels should be maintained between 5-15 mcg/m L for optimal bronchodilation. Monitor for toxicity (nausea, vomiting, tremor, tachycardia) especially in patients with hepatic impairment, heart failure, or concurrent use of CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine). Smoking induces theophylline metabolism requiring higher doses. Use with caution in elderly and patients with seizure disorders.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid consuming large amounts of caffeine-containing foods or beverages (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity such as persistent nausea, vomiting, rapid or irregular heartbeat, or seizures immediately.,Do not stop taking this medication abruptly; taper under medical supervision.,Inform your doctor of all medications you take, including over-the-counter drugs and herbal supplements.,If you smoke, tell your doctor; changes in smoking habits may require dose adjustment.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AQUAPHYLLIN vs AEROLATE JR, answered by our medical review team.
AQUAPHYLLIN is a Bronchodilator that works by Phosphodiesterase-3 (PDE3) inhibitor with additional adenosine receptor antagonism and weak inhibition of phosphodiesterase-4 (PDE4). Increases intracellular c AMP and c GMP, leading to bronchodilation and anti-inflammatory effects.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AQUAPHYLLIN and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AQUAPHYLLIN is: 300 mg orally every 6 hours as needed for acute asthma exacerbation; for chronic maintenance, 300 mg orally every 8 hours.. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AQUAPHYLLIN and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AQUAPHYLLIN is classified as Category C. Theophylline (Aquaphyllin) is pregnancy category C. First trimester: No well-controlled studies; risk cannot be ruled out. Second/third trimesters: Increased risk of neonatal apnea. AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.